Journal ArticleDOI
Blinatumomab as a bridge to further therapy in cases of overwhelming toxicity in pediatric B-cell precursor acute lymphoblastic leukemia: Report from the Israeli Study Group of Childhood Leukemia.
Sarah Elitzur,Nira Arad-Cohen,Shlomit Barzilai-Birenboim,Miriam Ben-Harush,Bella Bielorai,Bella Bielorai,Ronit Elhasid,Tamar Feuerstein,Gil Gilad,Alexander Gural,Mira Kharit,Naomi Litichever,Ronit Nirel,Sigal Weinreb,Ofir Wolach,Ofir Wolach,Amos Toren,Amos Toren,Shai Izraeli,Elad Jacoby,Elad Jacoby +20 more
Reads0
Chats0
TLDR
11 pediatric patients with ALL are reported to have been treated with blinatumomab following overwhelming chemotherapy‐associated toxicity, with recovery of all patients and successful bridging to further antileukemia therapy.Abstract:
Tremendous progress in the therapy of pediatric acute lymphoblastic leukemia (ALL) has been achieved through combination cytotoxic chemotherapy, leading to high cure rates, at the cost of significant life-threatening toxicity. The bispecific T-cell engager blinatumomab, recently approved for relapsed/refractory ALL, has a unique nonmyelotoxic toxicity profile. As blinatumomab causes B-cell depletion, the safety of its use during severe chemotherapy-induced toxicity is unclear. We report 11 pediatric patients with ALL, treated with blinatumomab following overwhelming chemotherapy-associated toxicity, with recovery of all patients and successful bridging to further antileukemia therapy. Blinatumomab can be considered for rare patients who cannot tolerate cytotoxic therapy.read more
Citations
More filters
Journal ArticleDOI
Immunotherapy in pediatric acute lymphoblastic leukemia
TL;DR: In this paper, the authors proposed to incorporate effective immunotherapy into ALL therapy to enable the intensity of conventional chemotherapy to be decreased and thereby reduce associated toxicity, leading to further improvement in survival and quality of life for patients with acute lymphoblastic leukemia.
Journal ArticleDOI
Immunotherapy in Pediatric B-Cell Acute Lymphoblastic Leukemia: Advances and Ongoing Challenges.
Sylwia Jasinski,Francis Andrew De Los Reyes,Gloria Paz Contreras Yametti,Joanna Pierro,Elizabeth A. Raetz,William L. Carroll +5 more
TL;DR: The clinical biology and treatment of B-ALL is discussed with an emphasis on the role of immunotherapy in overcoming the challenges of conventional cytotoxic therapy and strategies to address unique side effects associated with these agents are discussed.
Journal ArticleDOI
Blinatumomab in Pediatric Acute Lymphoblastic Leukemia-From Salvage to First Line Therapy (A Systematic Review).
Manon Queudeville,Martin Ebinger +1 more
TL;DR: In this article, a systematic review discusses all published results for blinatumomab in children as well as all ongoing clinical trials in R/R-ALL and concludes that the use of BLINATOMAB is beneficial for patients with a high risk of severe chemotherapy-associated toxicities.
Journal ArticleDOI
Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP).
José Luis Fuster,Agueda Molinos-Quintana,Carolina Fuentes,José Raúl Machado Fernández,Pablo Velasco,Toñi Pascual,Susana Rives,José Luis Dapena,Luisa Sisinni,Oriana López-Godino,Pilar Palomo,Marta Villa‐Alcázar,Francisco Bautista,Marta González-Vicent,Mónica López-Duarte,Marina García-Morín,Eduardo Ramos-Elbal,Manuel Ramírez +17 more
TL;DR: Blinatumomab and inotuzumab ozogamycin represent promising alternatives to conventional chemotherapy in acute lymphoblastic leukaemia and can be a useful tool to reduce minimal residual disease, and/or avoid further toxic chemotherapy until stem cell transplantation.
Journal ArticleDOI
Immunotherapy in Pediatric Solid Tumors—A Systematic Review
TL;DR: This review aims to discuss and summarize the main classes of immunotherapeutic approaches used to treat pediatric solid tumors.
References
More filters
Journal ArticleDOI
Acute Lymphoblastic Leukemia in Children
TL;DR: The most common cancer in childhood is now curable in 90% of patients and the subsets of acute lymphoblastic leukemia that are most resistant to current therapy are being targeted.
Journal ArticleDOI
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop M. Kantarjian,Anthony S. Stein,Nicola Gökbuget,Adele K. Fielding,Andre C. Schuh,Josep-Maria Ribera,Andrew H. Wei,Hervé Dombret,Robin Foà,Renato Bassan,Onder Arslan,Miguel A. Sanz,Julie Bergeron,Fatih Demirkan,Ewa Lech-Maranda,Alessandro Rambaldi,Xavier Thomas,Heinz-August Horst,Monika Brüggemann,Wolfram Klapper,Brent L. Wood,Alex Fleishman,Dirk Nagorsen,Chris Holland,Zachary Zimmerman,Max S. Topp +25 more
TL;DR: Treatment with blinatumomab resulted in significantly longer overall survival than chemotherapy among adult patients with relapsed or refractory B‐cell precursor ALL, and remission rates within 12 weeks after treatment initiation were significantly higher.
Journal ArticleDOI
Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
Ralf C. Bargou,Eugen Leo,Gerhard Zugmaier,Matthias Klinger,Mariele Goebeler,Stefan Knop,Richard Noppeney,Andreas Viardot,Georg Hess,Martin Schuler,Hermann Einsele,Christian Brandl,Andreas Wolf,Petra Kirchinger,Petra Klappers,Margit Schmidt,Gert Riethmüller,Carsten Reinhardt,Patrick A. Baeuerle,Peter Kufer +19 more
TL;DR: The clinical activity of a bispecific antibody construct called blinatumomab, which has the potential to engage all cytotoxic T cells in patients for lysis of cancer cells, is reported on.
Journal ArticleDOI
Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration
Ching-Hon Pui,Jun J. Yang,Stephen P. Hunger,Rob Pieters,Martin Schrappe,Andrea Biondi,Ajay Vora,André Baruchel,Lewis B. Silverman,Kjeld Schmiegelow,Gabriele Escherich,Keizo Horibe,Yves Benoit,Shai Izraeli,Allen Eng Juh Yeoh,Der Cherng Liang,James R. Downing,William E. Evans,Mary V. Relling,Charles G. Mullighan +19 more
TL;DR: The information gained from collaborative studies has helped decipher the heterogeneity of ALL to help improve personalized treatment, which will further advance the current high cure rate and the quality of life for children and adolescents with ALL.
Journal ArticleDOI
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia
Nicola Gökbuget,Hervé Dombret,Massimiliano Bonifacio,Albrecht Reichle,Carlos Graux,Christoph Faul,H. Diedrich,Max S. Topp,Monika Brüggemann,Heinz-August Horst,Violaine Havelange,Julia Stieglmaier,Hendrik Wessels,Vincent Haddad,Jonathan Benjamin,Gerhard Zugmaier,Dirk Nagorsen,Ralf C. Bargou +17 more
TL;DR: After treatment with blinatumomab in a population of patients with MRd-positive B-cell precursor ALL, a majority achieved a complete MRD response, which was associated with significantly longer RFS and OS compared with MRD nonresponders.